{"id":"placebo-digestive-tablet","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo effects operate via neurobiological pathways including expectation-driven dopamine release, endogenous opioid activation, and autonomic nervous system modulation. In digestive complaints, placebo can reduce symptoms through reduced anxiety, altered gut-brain signaling, and enhanced parasympathetic tone. The effect is particularly pronounced in functional gastrointestinal disorders where psychological factors contribute significantly to symptom perception.","oneSentence":"A placebo tablet produces therapeutic effects through the patient's psychological expectation and belief in treatment rather than through active pharmacological mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:36:07.677Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Functional digestive symptoms (as a control or therapeutic agent in clinical research)"}]},"trialDetails":[{"nctId":"NCT05634746","phase":"PHASE3","title":"24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2022-12-29","conditions":"Eosinophilic Esophagitis","enrollment":218},{"nctId":"NCT04906421","phase":"PHASE2","title":"Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Sagimet Biosciences Inc.","startDate":"2021-08-12","conditions":"Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease","enrollment":168},{"nctId":"NCT06958952","phase":"NA","title":"Evaluating the Efficacy of \"Digestive Aid\" in Functional Dyspepsia","status":"RECRUITING","sponsor":"Tehran University of Medical Sciences","startDate":"2025-04-15","conditions":"Dyspepsia Chronic","enrollment":50},{"nctId":"NCT06560879","phase":"PHASE2","title":"Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children with Leukemia","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Pediatrics, Mexico","startDate":"2025-02-01","conditions":"Probiotics, Gastrointestinal Diseases, Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":120},{"nctId":"NCT06320379","phase":"NA","title":"Zypan Functional Dyspepsia","status":"RECRUITING","sponsor":"National University of Natural Medicine","startDate":"2023-03-15","conditions":"Dyspepsia","enrollment":64},{"nctId":"NCT04281108","phase":"PHASE3","title":"Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2020-01-30","conditions":"Eosinophilic Esophagitis","enrollment":143},{"nctId":"NCT03191864","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Adare Pharmaceuticals, Inc.","startDate":"2017-06-22","conditions":"Eosinophilic Esophagitis","enrollment":106},{"nctId":"NCT04069611","phase":"NA","title":"Non Surgical Therapy of Periodontitis in Diabetes Patients: the Adjunctive Use of Probiotics","status":"UNKNOWN","sponsor":"Universidad Complutense de Madrid","startDate":"2020-01-30","conditions":"Diabetes, Periodontitis","enrollment":40},{"nctId":"NCT03850509","phase":"PHASE2","title":"Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2020-02-25","conditions":"Crohn's Disease","enrollment":3},{"nctId":"NCT01424228","phase":"PHASE4","title":"Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years","status":"COMPLETED","sponsor":"Shire","startDate":"2011-04-06","conditions":"Constipation","enrollment":364},{"nctId":"NCT02475369","phase":"PHASE4","title":"Pancreatic Enzyme Supplementation for Celiac Disease","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2015-05","conditions":"Celiac Disease","enrollment":21},{"nctId":"NCT02185794","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-06-13","conditions":"Hepatitis C Virus Infection","enrollment":101},{"nctId":"NCT00486512","phase":"PHASE3","title":"Chemoprevention of Colorectal Adenomas","status":"TERMINATED","sponsor":"Colotech A/S","startDate":"2007-06","conditions":"Adenomatous Polyps","enrollment":350},{"nctId":"NCT03050359","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-05","conditions":"Duodenal Ulcer","enrollment":533},{"nctId":"NCT04361695","phase":"NA","title":"Preemptive Analgesia for Hemorrhoidectomy","status":"UNKNOWN","sponsor":"Russian Society of Colorectal Surgeons","startDate":"2020-02-27","conditions":"Hemorrhoidectomy","enrollment":144},{"nctId":"NCT03733379","phase":"PHASE3","title":"Systemic Probiotics in the Periodontal Treatment","status":"UNKNOWN","sponsor":"Belén Retamal-Valdes","startDate":"2018-11-05","conditions":"Periodontitis","enrollment":176},{"nctId":"NCT04209777","phase":"PHASE3","title":"Clinical Evaluation of Smoker Periodontal Subjects After Lactobacillus-reuteri Probiotics and Antibiotics Therapy","status":"COMPLETED","sponsor":"Dow University of Health Sciences","startDate":"2018-07-08","conditions":"Periodontal Diseases, Smoking","enrollment":66},{"nctId":"NCT01130272","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea","status":"COMPLETED","sponsor":"Furiex Pharmaceuticals, Inc","startDate":"2010-04-28","conditions":"Irritable Bowel Syndrome","enrollment":807},{"nctId":"NCT03180632","phase":"PHASE2","title":"Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy:","status":"COMPLETED","sponsor":"St. Justine's Hospital","startDate":"2017-06-28","conditions":"Anxiety","enrollment":98},{"nctId":"NCT03639519","phase":"PHASE4","title":"A Trial to Assess the Impact of Ascorbic Acid on Cardiac Surgeries Outcomes and Complications''","status":"UNKNOWN","sponsor":"El-Galaa Military Medical Complex","startDate":"2018-04-15","conditions":"Cardiothoracic Surgery","enrollment":100},{"nctId":"NCT01553747","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)","status":"COMPLETED","sponsor":"Furiex Pharmaceuticals, Inc","startDate":"2012-05-29","conditions":"Irritable Bowel Syndrome","enrollment":1146},{"nctId":"NCT03420534","phase":"PHASE1","title":"Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2017-11-17","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT02830789","phase":"NA","title":"Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-12","conditions":"Roux-en-Y Gastric Bypass, Hyperparathyroidism, Secondary","enrollment":38},{"nctId":"NCT02984930","phase":"NA","title":"Effect of Proton Pump Inhibitor and Mosapride on Acid Pocket in Gastroesophageal Reflux Disease","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2016-12","conditions":"Gastroesophageal Reflux Disease","enrollment":30},{"nctId":"NCT00953706","phase":"PHASE2","title":"Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-09","conditions":"Cystic Fibrosis","enrollment":140},{"nctId":"NCT00357994","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-01","conditions":"Advanced Parkinson's Disease","enrollment":36},{"nctId":"NCT00660387","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-12","conditions":"Advanced Parkinson's Disease","enrollment":35},{"nctId":"NCT01871701","phase":"PHASE1","title":"Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2012-11","conditions":"Healthy","enrollment":40},{"nctId":"NCT02013323","phase":"PHASE2","title":"Clinical and Microbiological Efficacy of Systemic Ayurvedic Immunomodulator Septilin in the Treatment of Chronic Periodontitis","status":"COMPLETED","sponsor":"Government Dental College and Research Institute, Bangalore","startDate":"2013-03","conditions":"Chronic Periodontitis","enrollment":60},{"nctId":"NCT01906450","phase":"NA","title":"STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER HIGH SENSITIVE C-REACTIVE PROTEIN. RANDOMIZED CONTROLLED CLINICAL TRIAL.","status":"UNKNOWN","sponsor":"Universidad del Valle, Colombia","startDate":"2013-05","conditions":"Chronic Periodontitis","enrollment":75},{"nctId":"NCT01271231","phase":"NA","title":"Study on Periodontal Treatment in Diabetic Patients","status":"COMPLETED","sponsor":"Universidad de Antioquia","startDate":"2010-04","conditions":"Diabetes, Gingivitis, Periodontitis","enrollment":90},{"nctId":"NCT00909727","phase":"PHASE3","title":"Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-08","conditions":"Cystic Fibrosis","enrollment":52},{"nctId":"NCT01127282","phase":"PHASE4","title":"The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2009-12","conditions":"H1N1 Influenza","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":134,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo (digestive tablet)","genericName":"Placebo (digestive tablet)","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo tablet produces therapeutic effects through the patient's psychological expectation and belief in treatment rather than through active pharmacological mechanisms. Used for Functional digestive symptoms (as a control or therapeutic agent in clinical research).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}